Pioglitazone News and Research

RSS

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Among older adults with diabetes, certain subgroups--including white patients and those with lower incomes--were slower to discontinue the diabetes drug rosiglitazone after a US Food and Drug Administration safety alert, reports a study in the April issue of Medical Care.

17 Mar 2016

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

9 Mar 2016

Medical scientists examine potential new tool for helping prevent stroke, heart attack

Medical scientists just vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study recently published in the New England Journal of Medicine, researchers show that a drug reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.

26 Feb 2016

Findings offer new approach to treating metabolic disorders

A new research study has revealed an important relationship between proteins secreted by the heart and obesity, glucose intolerance, and insulin resistance. The findings, published today in Obesity, offer a new approach to treating metabolic disorders, including type 2 diabetes, by targeting the pathway that controls the proteins' concentration in the blood.

18 Feb 2016

Tackling insulin resistance may reduce recurrence after stroke

Giving pioglitazone to stroke survivors with insulin resistance but no overt diabetes reduces their risk of having a recurrent vascular event, shows the randomised Insulin Resistance Intervention after Stroke trial.

18 Feb 2016

Pioglitazone drug may prevent recurrent stroke and heart attacks

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes.

18 Feb 2016

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans.

11 Oct 2015

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Inside our bones there is fat. Diabetes increases the amount of this marrow fat. And now a study from the UNC School of Medicine shows how some diabetes drugs substantially increase bone fat and thus the risk of bone fractures.

9 Sep 2015

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co.'s $2.37 billion settlement didn't attract enough claimants to participate in the deal, which said the company would fund the deal after 95% of claimants joined it.

18 Aug 2015

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Takeda Pharmaceutical Company Limited today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a large (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS with up to 10 years of follow-up.

31 Jul 2015

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.

28 Jul 2015

Study shows glitazone antidiabetic drug may reduce risk of Parkinson’s disease

A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to a new study published in PLOS Medicine.

22 Jul 2015

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA.

22 Jul 2015

Pioglitazone drug significantly decreases risk of dementia

Patients with type 2 diabetes have a dysfunctional sugar metabolism because the essential hormone insulin does not work effectively. Once the disease reaches an advanced stage, the body stops producing insulin altogether, which means that it has to be administered externally.

23 Jun 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.

23 Apr 2015

Diabetes medication can help white blood cells fight bacterial infections

Pioglitazone, a medication approved for treatment of type 2 diabetes, can help bypass genetic defects in chronic granulomatous disease to help white blood cells fight bacterial infections, according to researchers at National Jewish Health.

12 Feb 2015

Study clarifies association between metformin use and lung cancer risk

Among nonsmokers who had diabetes, those who took the diabetes drug metformin had a decrease in lung cancer risk, according to a study in Cancer Prevention Research, a journal of the American Association for Cancer Research, by Lori Sakoda, PhD, MPH, research scientist at the Kaiser Permanente Division of Research in Oakland, California.

2 Feb 2015

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

26 Aug 2014

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone).

30 Jul 2014

Pioglitazone News and Research

Study finds disparities in discontinuing diabetes drug rosiglitazone following FDA safety alert

Metabolic syndrome treatment benefits MS patients

Medical scientists examine potential new tool for helping prevent stroke, heart attack

Findings offer new approach to treating metabolic disorders

Tackling insulin resistance may reduce recurrence after stroke

Pioglitazone drug may prevent recurrent stroke and heart attacks

FDA awards research grants to boost product development for patients with rare diseases

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Study shows glitazone antidiabetic drug may reduce risk of Parkinson’s disease

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Pioglitazone drug significantly decreases risk of dementia

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Study supports use of vitamin E as effective treatment for NASH

Diabetes medication can help white blood cells fight bacterial infections

Study clarifies association between metformin use and lung cancer risk

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News